JOHN JOHNSON
CIK 1410781 · Executive Chairman · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$6.66M
Companies
13
Total Filings
104
Lifetime Open-Market Net
-$3.23M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AXGN | Director | 14,150 | $42.10 | $595.8K | -$1.91M | 12 | 2026-06-26 |
| XERS | Director | 683,083 | $8.40 | $5.74M | -$1.85M | 10 | 2026-06-05 |
| VSTM | Director | 52,666 | $6.11 | $321.5K | $0 | 10 | 2026-05-26 |
| Applied Therapeutics, Inc. (APLT) Delisted | Executive Chairman | 500,000 | $0.10 | $51.5K | $0 | 1 | 2024-12-20 |
| Strongbridge Biopharma plc (SBBP) Delisted | Chief Executive Officer | 0 | $2.00 | $0 | $0 | 11 | 2021-10-06 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 0 | — | — | $0 | 8 | 2020-07-02 |
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) Delisted | Chief Executive Officer | 37,400 | — | — | -$72.4K | 5 | 2019-07-02 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | 0 | — | — | $0 | 5 | 2018-02-13 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Director | — | $15.00 | — | $0 | 1 | 2018-02-05 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | Director | 10,000 | — | — | $0 | 6 | 2017-01-05 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | Director | — | — | — | $0 | 2 | 2012-08-09 |
| SAVIENT PHARMACEUTICALS INC (SVNT) Delisted | Chief Executive Officer | 256,350 | — | — | $110.5K | 6 | 2012-01-04 |
| IMCLONE SYSTEMS INC (IMCL) Delisted | CEO | 0 | — | — | $500.0K | 4 | 2008-11-24 |
Recent Filings · Page 5 of 11
104 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-06-30 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2021-04-09 | Strongbridge Biopharma plc (SBBP) Delisted | Tax (F) | −17,325 | -$46.4K | EDGAR |
| 2021-01-08 | Strongbridge Biopharma plc (SBBP) Delisted | Grant (A) | +491,000 | $0 | EDGAR |
| 2020-07-07 | Strongbridge Biopharma plc (SBBP) Delisted | Grant (A) | +315,000 | $0 | EDGAR |
| 2020-07-02 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Disp (D) | −20,475 | -$368.6K | EDGAR |
| 2020-06-18 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2020-06-15 | PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Grant (A) | +7,281 | $0 | EDGAR |
| 2020-05-18 | Strongbridge Biopharma plc (SBBP) Delisted | Tax (F) | −15,348 | -$43.9K | EDGAR |
| 2020-04-29 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2020-04-10 | Strongbridge Biopharma plc (SBBP) Delisted | Grant (A) | +182,500 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.